BLANKETROL III, MODEL 233 AND COOLBLUE, MODEL 25-01 HYPER-HYPOTHERMIA SYSTEMS
K101589 · Cincinnati Sub-Zero Products, Inc. · DWJ · Sep 20, 2010 · Cardiovascular
Device Facts
| Record ID | K101589 |
| Device Name | BLANKETROL III, MODEL 233 AND COOLBLUE, MODEL 25-01 HYPER-HYPOTHERMIA SYSTEMS |
| Applicant | Cincinnati Sub-Zero Products, Inc. |
| Product Code | DWJ · Cardiovascular |
| Decision Date | Sep 20, 2010 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 870.5900 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The Blanketrol III Model 233 and CoolBlue Model 25-01 Hyper-Hypothermia Temperature Management Systems are used to lower or to raise a patient's temperature and/or maintain a desired patient temperature through conductive heat transfer. The system is composed of a heater, a compressor, a circulating pump and blankets/pads.
Device Story
Water-recirculating thermal management system; provides hypothermia, hyperthermia, or normothermia therapy. System components include heater, compressor, circulating pump, and disposable/reusable blankets/pads. Operates by pumping temperature-controlled water through flexible tubing to blankets/pads for conductive heat transfer to patient's external surface. Used in clinical settings; operated by healthcare providers. Output is patient temperature modulation; assists clinicians in achieving/maintaining target patient temperatures. Benefits include precise control of patient body temperature for therapeutic purposes.
Clinical Evidence
Bench testing only. Testing included temperature performance, system safety limit testing (high/low), transportation testing, and blanket structural integrity. Compliance with IEC 60601-1 and IEC 60601-1-2 standards verified.
Technological Characteristics
Water-recirculating thermal management system. Components: heater, compressor, circulating pump, flexible tubing, and blankets/pads. Energy source: electrical. Standards: IEC 60601-1 (General Safety), IEC 60601-1-2 (EMC).
Indications for Use
Indicated for patients requiring temperature management (hypothermia, hyperthermia, or normothermia) via conductive heat transfer using external blankets or pads.
Regulatory Classification
Identification
A thermal regulating system is an external system consisting of a device that is placed in contact with the patient and a temperature controller for the device. The system is used to regulate patient temperature.
Predicate Devices
- Cincinnati Sub-Zero Blanketrol Hyper-Hypothermia System, Model 200
- Gaymar Industries MediTherm II Series 5900 Hyper/Hypothermia System (K912051)
- M.T.R.E Advanced Technology Ltd. CritiCool device (K083662)
Related Devices
- K110104 — BLANKETROL II HYPER-HYPOTHERMIA TEMPERATURE MANAGMENT SYSTEM · Cincinnati Sub-Zero Products, Inc. · Feb 4, 2011
- K033021 — KIMBERLY-CLARK PATIENT WARMING SYSTEM - MODEL 100 CONTROL UNIT AND ENERGY TRANSFER PADS · Kimberly-Clark Corp. · Nov 12, 2003
- K120081 — NORM-O-TEMP HYPERTHERMIA SYSTEM INCLIDING BLANKETS/PADS · Cincinnati Sub-Zero Products, Inc. · Feb 17, 2012
- K100585 — MEDI-THERM HYPER/HYPOTHERMIA SYSTEM, MODELS MTA6900, MTA7900 · Gaymar Industries, Inc. · Jan 20, 2011
- K243942 — Arctic Sun Stat Temperature Management System · Medivance, Inc. · Apr 30, 2025
Submission Summary (Full Text)
{0}------------------------------------------------
510(k) Summary
- 1. COMPANY INFORMATION
Cincinnati Sub-Zero, Inc. 12011 Mosteller Road Cincinnati, Ohio 45241-1528 Telephone: (513) 772-8810 FAX: (513) 772-9119
SEP 2 0 2010
- 2. CONTACT INFORMATION
Steve J. Berke President and CEO Telephone: (513) 772-8810 ext. 3212 FAX: (513) 772-9119 Email: sjberke@cszinc.com
- 3. DATE PREPARED: June 4, 2010 1
- 4. DEVICE TRADE NAME: Blanketrol III Model 233 Hyper-Hypothermia System, CoolBlue Model 25-01 Hyper-Hypothermia System when sold by Innercool Therapies Inc.
- 5. COMMON NAME: Temperature management system
- 6. CLASSIFICATION NAME: System, Thermal Regulating
- 7. CLASSIFICATION REGULATION: 21 CFR 870.5900
- 8. CLASSIFICATION PRODUCT CODE: DWJ
- 9. PANEL: CARDIOVASCULAR
- 10. DEVICE CLASSIFICATION: Class II
## 11. IDENTIFICATION OF PREDICATES:
- a. Cincinnati Sub-Zero Blanketrol Hyper-Hypothermia System, Model 200 (pre-amendment device)
- b. Gaymar Industries MediTherm II Series 5900 Hyper/Hypothermia System (K912051)
- M.T.R.E Advanced Technology Ltd. CritiCool device (K083662) C.
{1}------------------------------------------------
## Cincinnati Sub-Zero, Inc. 510(k) Premarket Notification for Blanketrol III Model 233/CoolBlue devices
### DEVICE DESCRIPTION
The Blanketrol III/CoolBlue Hyper-Hypothermia System is a water (liquid) recirculating device providing either hypothermia, hyperthermia or normothermia treatment as determined by the health care provider.
Water is either heated or cooled depending on the need of the patient. The heated or cooled water is pumped through connecting flexible tubing to a disposable or reusable pad or blanket to provide patient therapy for a site specific external surface area or for whole body surface temperature therapy by the means of conductive heat transfer.
#### INTENDED USE
The Blanketrol III Model 233 and CoolBlue Model 25-01 Hyper-Hypothermia Temperature Management Systems are used to lower or to raise a patient's temperature and/or maintain a desired patient temperature through conductive heat transfer. The system is composed of a heater, a compressor, a circulating pump and blankets/pads.
## BENCH TESTS PERFORMED IN DETERMINATION OF SUBSTANTIAL EQUIVALENCE
Bench testing was performed in order to validate the design according to the company's specified design requirements, and to demonstrate the new systems are substantially equivalent to the predicate devices.
The following bench tests were performed:
- Temperature Performance Testing .
- System Safety Limit Testing (high and low limits) .
- Transportation Testing .
- Blanket Structural Integrity Testing .
In addition, the new systems meet the applicable requirements of the following standards:
- IEC 60601-1, Medical Electrical Equipment Part 1: General Requirements for . Safety, 1988; Amendment 1, 1991-11, Amendment 2, 1995.
- IEC 60601-1-2, Medical Electrical Equipment Part 1-2: General Requirements . for Safety - Collateral Standard: Electromagnetic Compatibility -- Requirements and Tests.
All necessary testing has been performed for the Blanketrol III and CoolBlue Hyper-Hypothermia Temperature Management Systems to assure substantial equivalence to the predicate devices.
#### SUBSTANTIAL EQUIVALENCE
The new devices have the same intended use as the predicates and similar technological characteristics that do not raise new types of questions of safety and effectiveness and are therefore substantially equivalent to the predicate devices.
{2}------------------------------------------------
# DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird-like figure.
#### Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Cincinnati Sub-Zero c/o Mr. Steven J. Berke President and CEO 12011 Mosteller Road Cincinnati, OH 45241-1528
SEP 2 0 2010
Re: K101589
Blanketrol III Model 233 and CoolBlue Model 25-01 Hyper/Hypothermia Systems Regulation Number: 21 CFR 870.5900 Regulation Name: Thermal Regulating System Regulatory Class: Class II (two) Product Code: DWJ Dated: September 13, 2010 Received: September 15, 2010
Dear Mr. Berke:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be
{3}------------------------------------------------
Page 2 - Mr. Steven J. Berke
found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Dunia R. Varner
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure ·
{4}------------------------------------------------
Indications for Use
K101589 SEP 2 0 2010
510(k) Number (if known): _ )<10 | 589
Device Name: Blanketrol III Model 233 and CoolBlue Model 25-01 Hyper-Hypothermia Temperature Management Systems
Indications for Use:
The Blanketrol III Model 233 and CoolBlue Model 25-01 Hyper-Hypothermia Temperature Management Systems are used to lower or to raise a patient's temperature and/or maintain a desired patient temperature through conductive heat transfer. The system is composed of a heater, a compressor, a circulating pump and blankets/pads.
Prescription Use X (Part 21 CFR 801 Subpart D)
- - - - - - - - - - - - - - -
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
DWM R. VC. Ames
(Division Sign-Off)
Division of Cardiovascular Devices
Page 1 of 1
(Posted November 13, 2889)(k) Number__________________________________________________________________________________________________________________________________________
Submission Page: 14